Aethlon Medical (NASDAQ:AEMD) Upgraded at StockNews.com

StockNews.com upgraded shares of Aethlon Medical (NASDAQ:AEMD) to a sell rating in a research note released on Wednesday.

Separately, HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Aethlon Medical in a research report on Thursday, January 30th.

Aethlon Medical Price Performance

Shares of NASDAQ AEMD opened at $0.58 on Wednesday. The stock has a market capitalization of $8.44 million, a PE ratio of -0.37 and a beta of 1.88. Aethlon Medical has a fifty-two week low of $0.24 and a fifty-two week high of $1.85. The business has a fifty day moving average price of $0.65 and a two-hundred day moving average price of $0.49.

Aethlon Medical (NASDAQ:AEMD) last posted its quarterly earnings data on Wednesday, February 12th. The medical equipment provider reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.09. On average, equities analysts expect that Aethlon Medical will post -0.82 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in AEMD. Boothbay Fund Management LLC bought a new stake in shares of Aethlon Medical during the fourth quarter worth $186,000. Virtu Financial LLC acquired a new position in Aethlon Medical in the 4th quarter valued at approximately $81,000. Sassicaia Capital Advisers LLC bought a new position in shares of Aethlon Medical during the fourth quarter valued at $31,000. Allegiance Financial Group Advisory Services LLC bought a new stake in shares of Aethlon Medical in the fourth quarter worth $26,000. Finally, Renaissance Technologies LLC bought a new position in Aethlon Medical during the 4th quarter worth $25,000. Institutional investors own 1.99% of the company’s stock.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.